Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000978

Drug Information
NameMethylergonovine
Synonyms479-03-8; 78207-86-0; Ryegonovin; BRD-K34685430-001-01-1; HSDB 3364; (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-6-methyl-9,10-didehydroergoline-8-carboxamide; Ergoline-8-beta-carboxamide, 9,10-didehydro-N-((S)-1-(hydroxymethyl)propyl)-6-methyl-; DivK1c_000357; Methergine; D08207; BPBio1_000581; Ergotyl (TN); SPBio_000546; KBioSS_000743; Methylergometrine maleate; Spametrin-M; DB00353; Methylergometrine [INN:BAN]; Metenarin; UNII-W53L6FE61V; Methylergometrinum [INN-Latin]; EINECS 204-027-0; IDI1_000357; Methergin; Methylergometrine (INN); NINDS_000357; CID8226; Prestwick3_000374; methylergonovine; 29589-73-9; BSPBio_002023; Metilergometrinio; N-(alpha-(Hydroxymethyl)propyl)-D-lysergamide; Ergoline-8-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-6-methyl-, (8beta(S))-; 9,10-Didehydro-N-(alpha-(hydroxymethyl)propyl)-6-methyl-ergoline-8-beta-carboxamide; Spectrum3_000502; D-Lysergic acid-(+)-butanolamide-(2); Methylergometrinum; Methylergometrin; BSPBio_000527; Biomol-NT_000154; Lysergic acid butanolamide; LS-64363; Partergin; Ergometrine, methyl-; KBio2_000743; KBio2_003311; Ergotyl; 113-42-8; Methylergometrine; Methergen; Methylergobasine; AC1L1QJP; Lopac0_000794; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-6-methylergoline-8-carboxamide; Spectrum5_001879; Methylergobrevin; NCGC00024646-03; Methylergonovin; BPBio1_000442; NCGC00017258-05; Spectrum2_000613; D-Lysergic acid-dl-hydroxybutylamide-2; C20H25N3O2; 29477-86-9; ME 277; Spectrum_000263; KBio2_005879; KBio3_001523; AB00514664; Basofortina; Lysergamide, N-((S)-1-(hydroxymethyl)propyl)-; NCGC00024646-02; Metilergometrina; Metilergometrina [DCIT]; BRD-K34685430-050-04-2; Methylergobasin; KBio1_000357; Metilergometrinio [INN-Spanish]
Trade NameMethergine
IndicationExcessive bleeding
[ICD9: 459.0   ICD10: R58]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C20H25N3O2/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12
(9-21-17)8-18(16)23(2)10-13/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-
2H3,(H,22,25)/t13-,14+,18-/m1/s1
InChIKeyUNBRKDKAWYKMIV-QWQRMKEZSA-N
Canonical SMILESCCC(CO)NC(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C    
Isomeric SMILESCC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
Therapeutic ClassOxytocics
CAS NumberCAS 113-42-8
FormulaC20H25N3O2
PubChem Compound IDCID 8226.
PubChem Substance IDSID 151359.
SuperDrug ATC IDG02AB01
SuperDrug CAS ID000113428;
TargetD(1) dopamine receptorAntagonist[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 006035 To Reference
Ref 2Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543